Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PELL Bio-Med Technology CoTPE:6949 +9.72%18 Debt-to-Equity is 0.09 as of Jun. 2026, which is 57% below its 10-year median of 0.21. GuruFocus rates TPE:6949 with a GF Score™ of 18/100. The stock has 4 warning signs investors should review. Among 954 Biotechnology companies, PELL Bio-Med Technology Co ranks better than 62.16% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for PELL Bio-Med Technology Co's Debt-to-Equity or its related term are showing as below:
TPE:6949'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.09 Med: 0.21 Max: 0.63
Current: 0.09
During the past 5 years, the highest Debt-to-Equity Ratio of PELL Bio-Med Technology Co was 0.63. The lowest was 0.09. And the median was 0.21.
TPE:6949's Debt-to-Equity is ranked better than 62.16% of 954
companies
in the Biotechnology industry
Industry Median: 0.16
vs TPE:6949: 0.09
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
PELL Bio-Med Technology Co Debt-to-Equity Related Terms
PELL Bio-Med Technology Co Debt-to-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TPE:6949 vs VRTX, REGN, RVMD: Debt-to-Equity Comparison
For the Biotechnology subindustry, PELL Bio-Med Technology Co's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PELL Bio-Med Technology Co Debt-to-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, PELL Bio-Med Technology Co's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where PELL Bio-Med Technology Co's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PELL Bio-Med Technology Co (TPE:6949) has a Debt-to-Equity of 0.09 as of Jun. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on PELL Bio-Med Technology Co and its competitors. This is 57% below median its historical median of 0.21. Over the past decade, PELL Bio-Med Technology Co's Debt-to-Equity has ranged from 0.09 to 0.63. According to the industry distribution chart, PELL Bio-Med Technology Co ranks #361 out of 954 companies in the Biotechnology industry, placing it in the top 37.8%.
Is PELL Bio-Med Technology Co's Debt-to-Equity too high?
PELL Bio-Med Technology Co's current Debt-to-Equity of 0.09 is 57% below median its 10-year median of 0.21. Over the past 10 years, this metric has ranged from a low of 0.09 to a high of 0.63. The Biotechnology industry median Debt-to-Equity is 0.16. PELL Bio-Med Technology Co's value of 0.09 is 43.8% below this industry median. Based on the distribution chart, PELL Bio-Med Technology Co ranks #361 out of 954 companies in the Biotechnology industry, which is above the industry midpoint. Overall, PELL Bio-Med Technology Co has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does PELL Bio-Med Technology Co's Debt-to-Equity compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, PELL Bio-Med Technology Co ranks #361 out of 954 companies for Debt-to-Equity. This puts PELL Bio-Med Technology Co in the upper half of its industry. The industry median Debt-to-Equity is 0.16. PELL Bio-Med Technology Co's value of 0.09 is 43.8% below this benchmark. Historically, PELL Bio-Med Technology Co's own Debt-to-Equity has ranged from 0.09 to 0.63 over the past decade. While the company's 10-year median is 0.21 vs. the industry median of 0.16, PELL Bio-Med Technology Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 954 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PELL Bio-Med Technology Co's current Debt-to-Equity of 0.09 is 43.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on PELL Bio-Med Technology Co and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PELL Bio-Med Technology Co's current Debt-to-Equity is 0.09, which is 57% below median its own 10-year median of 0.21. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PELL Bio-Med Technology Co stock overvalued right now?
PELL Bio-Med Technology Co (TPE:6949) has a current Debt-to-Equity of 0.09. The current Debt-to-Equity is 0.09, which is 57% below median its 10-year median of 0.21 and 43.8% below the Biotechnology industry median of 0.16. PELL Bio-Med Technology Co's overall GF Score™ is 18/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For PELL Bio-Med Technology Co (TPE:6949), the current Debt-to-Equity is 0.09 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
PELL Bio-Med Technology Co Ltd is a company engaged in the research and development and application of autologous T Cell Therapy (Adoptive T Cell Therapy), CAR-T (Chimeric Antigen Receptor T cell), and Gene-Modified Adipose-Derived Stem Cell (Gene-Modified Adipose-Derived Stem Cell). The company's segments includes Cell products, Consulting services, and Others.
18GF Score
Get the complete analysis for TPE:6949
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:6949 has been successfully added to your 
